Various alphabetized medical records
Industries

Life Sciences Intellectual Property

CRA has assisted clients in intellectual property (IP) matters concerning products and services in the life sciences sector, including Hatch-Waxman and BPCIA matters. We have also addressed patent, trademark, and copyright infringement, trade secret misappropriation, and IP licensing. Our experts have quantified damages based on lost profit and reasonable royalty methods and provided opinions on irreparable harm. In addition, we have experience addressing other forms of relief, such as rescission and disgorgement.

Our understanding of the unique dynamics of different therapeutic areas informs assessments of commercial success as a secondary indicator of non-obviousness and the claimed nexus between patented technologies and product success.

Engagements

  • 01
    Damages due to misappropriation of trade secrets and confidential information by multiple parties
    CRA calculated actual loss, reasonable royalty damages, and unjust enrichment due to the plaintiff. Dr. Gregory K Bell provided opening and reply reports and...
    View engagement
  • 02
    Lost profit damages due to manufacturer for alleged counterfeit sales
    CRA calculated the lost profits due to the manufacturer for the counterfeit drug products sold and distributed by the defendants. CRA’s analysis assisted...
    View engagement
  • 03
    AAA dispute in commercially reasonable efforts to market a hospital administered drug
    CRA expert, Dr. Sean Sheridan considered the Respondent’s efforts as they relate to the obligations of the licensing agreement and evaluated those efforts...
    View engagement

Contact a Life Sciences Intellectual Property expert.

See all Life Sciences Intellectual Property experts

Subscribe to receive our latest Insights.

Subscribe